@misc{oai:repo.qst.go.jp:00077532,
 author = {坂下, 哲哉 and 大島, 康宏 and 河野, 暢明 and 横田, 裕一郎 and 渡辺, 茂樹 and 佐々木, 一郎 and 石岡, 典子 and 荒川, 和晴 and Sakashita, Tetsuya and Oshima, Yasuhiro and Yokota, Yuuichiro and Watanabe, Shigeki and Sasaki, Ichiro and Ishioka, Noriko},
 month = {Nov},
 note = {Targeted α-particle therapy is a promising option for patients with malignant pheochromocytoma. Recent observations of α-emitting meta-[At-211]-astato-benzylguanidine ([At-211]-MABG) in a pheochromocytoma mouse model showed a strong anti-tumor effect [1], though the molecular mechanism remained elusive. Here, we show the comprehensive RNA-sequencing (RNA-seq) data for rat pheochromocytoma cell line PC12 cells based on in vitro [At-211]-MABG administration experiments. Enrichment analysis of differentially expressed genes (DEGs) and analysis of the gene expression profiles of cell cycle checkpoints revealed the mode of cell death via the p53-p21 signaling pathway after [At-211]-MABG treatment. Only p53-targeted genes were ranked among representative DEGs for decreased survival at all time points. Also, we estimated the low fluence rate of α-particles in in vitro [At-211]-MABG administration, approximately “one α-particle emission per one cell in one hour” for 10% survival. Long-lasting p53-induced signaling may break the wall of the “low fluence rate” in PC12 tumor cell death to exert anti-tumor effects. We recently published these findings on RNA-seq of in vitro PC12 transcriptome, suggesting that p53-p21 signaling pathway was an important cell death mechanism in anti-tumor effect of [At-211]-MABG [2].

References: 
[1] Y. Ohshima et al., Eur J Nucl Med Mol Imaging, 2018. 
[2] Y. Ohshima et al., Theranostics, 2019, 日本放射線影響学会第62回大会},
 title = {Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway},
 year = {2019}
}